+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Hypercholesterolemia Drug"

From
Hypercholesterolemia - Pipeline Review, H2 2020 - Product Thumbnail Image

Hypercholesterolemia - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 269 Pages
  • Global
From
Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Review, H2 2019 - Product Thumbnail Image

Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 118 Pages
  • Global
From
From
Heterozygous Familial Hypercholesterolemia (heFH) - Pipeline Review, H2 2020 - Product Thumbnail Image

Heterozygous Familial Hypercholesterolemia (heFH) - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 116 Pages
  • Global
From
From
Loading Indicator

The Hypercholesterolemia Drug market is a subset of the Cardiovascular Drugs market, which focuses on the treatment of high cholesterol levels. Hypercholesterolemia drugs are used to reduce the amount of cholesterol in the blood, which can help reduce the risk of heart attack and stroke. These drugs are typically prescribed to patients with high cholesterol levels, or those at risk of developing cardiovascular disease. Commonly prescribed drugs include statins, bile acid sequestrants, fibrates, and cholesterol absorption inhibitors. The Hypercholesterolemia Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Merck, Sanofi, AstraZeneca, Novartis, and Bristol-Myers Squibb. Show Less Read more